Skip to Content
Search Menu

ASH | American Society of Hematology Meeting & Exposition

ASH 2024

Betty Gardie & François Girdon

LBA-2: A New Cause of Hereditary and Acquired Erythrocytosis

/ Betty Gardie / Francois Girodon
ASH24 Play the Video

Fabian Müller

Treatment of Autoimmune Patients with CD19-CAR T Cells Results in Long-Term Drug-Free Remission or No Progression

/ Fabian Mueller
ASH24CAR-T Play the Video
Alexander Fuglkjær

Machine Learning Can Reduce Unnecessary Hospitalizations for Cancer Patients

/ Alexander Fuglkjær
AIASH24Lymphoma Play the Video
Muhammad Kashif

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Muhammad Kashif
AIASH24Myeloma Play the Video
Ingrid Glimelius

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Ingrid Glimelius
ASH24CLL Play the Video
Ingrid Glimelius

Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024

/ Ingrid Glimelius
ASH24Lymphoma Play the Video
Ingrid Glimelius

High Mortality Rate for Patients with Mantle Cell Lymphoma with a Second Primary Malignancy

/ Ingrid Glimelius
ASH24Lymphoma Play the Video

AI Will Play a Significant Role in All Aspects of Hematology in the Future

/ Andrew Srisuwananukorn
AIASH24 Play the Video
Mats Jerkeman

Based on Zuma-7 Studies CAR T-Cell Therapy Is Now Standard Treatment for B-Cell Lymphoma in Scandinavia

/ Mats Jerkeman
ASH24B-Cell Lymphoma Play the Video
Meletios-Athanasios Dimopoulos

Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

/ Meletios A. Dimopoulos
ASH24Myeloma Play the Video
Frida Bugge Askeland

Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma

/ Frida Bugge Askeland
ASH24Myeloma Play the Video
Jelena Jelicic

The Challenge of Selecting Patients with Diffuse Large-Based Cell Lymphoma Who Could Benefit Most from Clinical Trials

/ Jelena Jelicic
ASH24B-Cell Lymphoma Play the Video
Timothy Fenske

The Majority of Patients with Mantle Cell Lymphoma Probably Don’t Need Auto-Transplant in the Current Treatment Era

/ Timothy S. Fenske
ASH24Lymphoma Play the Video
Mats Jerkeman

There Is Definitely A Need for Novel Treatments for Elderly Patients with Mantle Cell Lymphoma

/ Mats Jerkeman
ASH24Lymphoma Play the Video
Fredrik Schjesvold

ASH 2024 Highlights: Early Smouldering Myeloma Treatment and Breakthrough Therapies in Multiple Myeloma Take Center Stage

/ Fredrik Schjesvold
ASH24Myeloma Play the Video
Paolo Ghia

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

/ Paolo Ghia
ASH24CLL Play the Video
Load more

ASH 2023

ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL

/ Hematology / BestPractice Nordic

ASH 2023: FDA Approves Gene Therapies for Sickle Cell Disease

/ Hematology / BestPractice Nordic

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

/ Hematology / BestPractice Nordic

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

/ Hematology / BestPractice Nordic

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ Hematology / BestPractice Nordic

Hematalogy 2023 • Meet the experts

Get access

2023

Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymphoma Play the Video
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video
Jason Westin

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

/ Jason Westin
ASH23B-Cell Lymphoma Play the Video
Eva Birgitte Leinøe

Undiagnosed and Unrecognized Patients with a High Bleeding Score

/ Eva Birgitte Leinøe
ASH23 Play the Video
Pieter Sonneveld

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

/ Pieter Sonneveld
ASH23Myelooma Play the Video
Jeff P. Sharman

No increase risk of Ventricular Arrhythmias and Sudden Death with Acalabrutinib

/ Jeff P. Sharman
ASH23 Play the Video
Gabriel Brisou

Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B-Cell Lymphoma

/ Gabriel Brisou
ASH23B-Cell Lymphoma Play the Video
Hamish Scott & Chris Hahn

ERG deficiency syndrome – maybe a new disease

/ Hamish S. Scott / Christopher Hahn
ASH23 Play the Video
Jeff P. Sharman

Acalabrutinib in Frontline CLL Treatment: Six-Year Results from the Elevate-TN Study

/ Jeff P. Sharman
ASH23CLL Play the Video
Amer Zeidan

New Data on Oral Decitabine in MDS: Real-Life Analysis and Outcomes from ASH2023

/ Amer Zeidan
ASH23 Play the Video
Mats Jerkeman

Key Updates in Mantle Cell Lymphoma from ASH 2023

/ Mats Jerkeman
ASH23Lymphoma Play the Video

CLL: Exciting to Await the New Guidelines, Approved by Danish Authorities

/ Lisbeth Enggaard
ASH23CLL Play the Video
Load more

EHA | Congress

We cover the most interesting news from the EHA Congress through abstracts, online articles and MEDtalk videos from experts and specialists worldwide.

Go to page

Oncology / Hematology • No. 15 • 2023

  • Breast Cancer Focus
  • ESMO 2023
  • Half of Male Lymphoma Survivors Suffer from Erectile Dysfunction
Get access

Latest MEDtalks from ASH 2022

Christine Ryan

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Christine Ryan
ASH22CLL Play the Video
Ryan Jacobs

CLL – The impact of using ibrutinib as front-line treatment

/ Ryan Jacobs
ASH22CLL Play the Video
Eunice Wang

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Eunice Wang
AMLASH22 Play the Video
Load more

Late-Breaking from ASH22 – Let’s Keep the Standard Consolidation Therapy with HDC-ASCT for PCNSL Patients

  • / BestPractice Nordic

Late-Breaking from ASH22 – Zanubrutinib has Now Proven Superiority to Ibrutinib

/ Hematology / BestPractice Nordic

ASH22 – Building Solutions to Challenges in Health Equity

/ Hematology / BestPractice Nordic

ASH 2022 in New Orleans – The Premier Event in Hematology 

/ Hematology / BestPractice Nordic

ASH 2021 abstracts

The ASH Annual Meeting provides several resources on COVID-19 in hematology

/ BestPractice Nordic
ASH21COVID-19
ASH21 poster hall

Long-term remission found with combination therapy for young patients with CLL

/ BestPractice Nordic
ASH21CLL

New prophylactic therapy for patients with hemophilia A and B

/ BestPractice Nordic
ASH21

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

/ BestPractice Nordic
ASH21

ZUMA-7: CAR T-cell therapy in earlier lines of therapy benefits patients with relapsed/refractory large B-cell lymphoma

/ BestPractice Nordic
ASH21CAR-TLymphoma

Isatuximab in combination with RVd improves MRD negativity

/ BestPractice Nordic
ASH21Myeloma

ASH 2021 MEDtalks

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

/ Paul G. Richardson
ASH21Myeloma Play the Video
Andrew H. Wei

Maintenance therapy: Oral azacitidine in patients with AML improves long-term overall survival

/ Andrew Wei
AMLASH21 Play the Video
Alexander Fosså

Perspective on the future standard of care for second-line treatment for patients with R/R LBCL

/ Alexander Fosså
ASH21Lymphoma Play the Video
Bjørn Tore Gjertsen

Relapse vaccine is a promising treatment for patients with AML

/ Bjørn Tore Gjertsen
AMLASH21 Play the Video
Manali Kamdar

CAR T Cell Therapy – a new standard of care for 2L treatment of R/R in Large B-cell Lymfoma

/ Manali Kamdar
ASH21Lymphoma Play the Video
Matthew S. Davids

ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL

/ Matthew S. Davids
ASH21CLL Play the Video
Paolo Ghia

How can we use Minimal Residual Disease in the treatment of CLL?

/ Paolo Ghia
ASH21CLL Play the Video
Fredrik Schjesvold

The use of FDG PET/CT positivity as an indication for consolidation in myeloma patients after ASCT

/ Fredrik Schjesvold
ASH21Myeloma Play the Video
Frederick L. Locke

Real-world outcomes of axi-cel treatment of large B-cell lymphoma

/ Frederick L. Locke
ASH21 Play the Video
Claudio Cerchione:

The best treatment sequence for first-, second-, and third-line therapy for patients with relapsed multiple myeloma

/ Claudio Cerchione
ASH21Myeloma Play the Video
Talha Munir

MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients

/ Talha Munir
ASH21CLL Play the Video
Philipp Sergeev

Combination treatment of AML with spleen tyrosine kinase

/ Philipp Sergeev
AMLASH21 Play the Video
Load more

Order the BestPractice Nordic magazine directly to your address for free.

Register and update your profile here.

Sign up

Onkologia / Hematologia • Nr. 7 • 2021

  • Suolistosyöpäseulonta
  • Syöpäsolujen leviämismekanismit
  • ROR1-reseptori
Get access

Lisää ASH 2020

ASH2020: Early vs Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

/ Aurore Perrot
ASH20 Play the Video

ASH2020: New Treatment Relapsed/Refractory Mantle Cell Lymphoma – data from phase 1 study

/ Maria Lia Palomba
ASH20 Play the Video

ASH2020: DARA to Rd continues to demonstrate a superior PFS benefit

/ Shaji K. Kumar
ASH20 Play the Video

ASH2020: Promising clinical response for CD19-CART-cell therapy in CLL

/ Ohad Benjamini
ASH20 Play the Video

ASH2020: The First-in-Class Anti-CD47 Antibody for AML

/ David A. Sallman
ASH20 Play the Video

ASH2020: Recurrent Crebbp Mutations in Follicular Lymphoma

/ Joe Schroers-Martin
ASH20 Play the Video

ASH2020: Promising results for treatment of AML

/ Tapan M. Kadia
ASH20 Play the Video

ASH2020: Updated efficacy data of maintenance therapy with DARA Plus RVd

/ Jonathan Kaufman
ASH20 Play the Video

Ruxolitinib is a major step forward for patients with chronic GVHD – where corticosteroids are inadequate

/ BestPractice Nordic
ASH20

Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%

/ BestPractice Nordic
ASH20Myeloma

ASH2020: Promising results for treatment of AML

/ BestPractice Nordic
ASH20Leukemia

ASH2020: Talquetamab, first-in-class bispecific antibody for patients with RRMM

/ Ajai Chari
ASH20Myeloma Play the Video
Mere
Back to top